Development of renal bone disease

European Journal of Clinical Investigation

Volumn 36, Issue SUPPL. 2, 2006, Pages 2-12

  Ferreira, A ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Bone biopsy; Cytokines; Growth factors; Renal osteodystrophy; Uraemia

Indexed keywords

ALUMINUM; CALCITONIN; CALCITRIOL; CALCIUM; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 2; INTERLEUKIN 6; OSTEOCALCIN; PARATHYROID HORMONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D RECEPTOR;

ADYNAMIC BONE DISEASE; AUTOCRINE EFFECT; BONE BIOPSY; BONE DISEASE; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; CELL ACTIVATION; CHRONIC KIDNEY FAILURE; HISTOLOGY; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; IMMUNOCYTOCHEMISTRY; MINERAL METABOLISM; OSTEITIS FIBROSA; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOMALACIA; PARACRINE SIGNALING; PATHOGENESIS; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; SENSITIVITY AND SPECIFICITY; UREMIA;

BONE AND BONES; CALCITRIOL; CYTOKINES; HUMANS; HYPOCALCEMIA; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY FAILURE, CHRONIC; OSTEITIS FIBROSA CYSTICA; OSTEOMALACIA; PARATHYROID HORMONE; PHOSPHORUS; RECEPTORS, CALCITRIOL; RENAL OSTEODYSTROPHY;

EID: 33745925911     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2006.01661.x     Document Type: Review

References (96)

1. Green J. The physiochemical structure of bone: cellular and non cellular elements. Miner Eletrolyte Metab 1994;29:7-15.
2. Hruska KA, Teitelbaum SL. Mechanisms of disease: renal osteodystrophy. N Engl J Med 1995;333:166-74.
3. Hruska KA. New concepts in renal oeteodystrophy. Nephrol Dial Transplant 1998;13:2755-60.
4. Marie JP, de Vernejoul MC. Derived osteoblastic cells and control of bone formation. Bone 1993;14:463-8.
5. Steddon SJ, McIntyre CW, Schroeder NJ, Burrin JM, Cunningham J. Impaired release of interleukin-6 from human osteoblastic cells in the uremic milieu. Nephrol Dial Transplant 2004;19:3078-83.
6. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
7. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis - inhibitory factor and is identical to TRACE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602.
8. Boyle WB, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
9. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999;140:4367-70.
10. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mecanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999;140:4382-9.
11. Grey A, Mitnick MA, Masiukiewicz U, Sun BH, Jilka RL. A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology 1999;140:4683-90.
12. Manolagas SC, Jilka RL. Bone Marrow, cytokines and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305-11.
13. Roodman GD. Advances in bone biology: the osteoclasts. Endocrine Rev 1996;17:308-52.
14. Drake FH, Doods RA, James IE, Connor JR, Debouck C, Richardson S et al. Cathepsin K, but not cathepsins B, L, or S is abundantly expressed in human osteoclasts. J Biol Chem 1996;271:12511-6.
15. Coburn JW. Renal osteodystrophy. Kidney Int 1980;17:677-89.
16. Kanis JA, Russel RG. Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1-alpha-hydroxylated derivatives. Br Med J 1977;1:78-81.
17. Naveh-Many T, Marx R, Keshet E, Pike JW, Silver J. Regulation of 1,25-dihidroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest 1990;86:1968-75.
18. Kremer R, Goltzman D, Hendy GN. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 1989;125:935-41.
19. Bricker NS. On the pathogenesis of the uremic state. An exposition of the 'trade-off hypothesis'. N Engl J Med 1972;286:1093-9.
20. Brown EM. Mechanisms underlying the regulation of parathyroid hormone secretion. Curr Opin Nephrol Hypertens 1993;2:541-51.
21. Silver J, Kilav R, Naveh-Many P. Mechanisms of secondary hyperparathyoidism. Am J Physiol Renal Physiol 2002;283:F367-76.
22. Almaden Y, Felsenfeld A, Rodriguez M, Cañadilas S, Luque F, Bas A et al. Proliferation in hyperplastic human and normal rat parathyroid glands: role of phosphate, calcitriol and gender. Kidney Int 2003;64:2311-7.
23. Rodriguez M, Martin-Malo A, Martinez M, Torres A, Felsenfeld A. Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effect on calcitriol. Kidney Int 1991;40:1055-62.
24. Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997;29:496-502.
25. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcaemia, hypercalcaemia and vitamin D in the rat. J Clin Invest 1990;86:1313-9.
26. Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ et al. Correlation of bone histology with parathyroid hormone, vitamin D3 and radiology in end-stage renal disease. Kidney Int 1993;44:1071-7.
27. Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990;38:193-211.
28. Sherrard DJ, Hercz G, Pey Y, Maloney NA, Greenwood C, Mannuel A et al. The spectrum of bone disease in end-stage renal failure: an evolving disorder. Kidney Int 1993;43:436-42.
29. Rao SD, Shih M-S, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erytropoietin in uremia. N Engl J Med 1993;328:171-5.
30. 2+ sensing receptor from bovine parathyroid. Nature 1993;366:575-80.
31. 2+ sensing receptor gene cause familial hypocalciuric hypercalcaemia and neonatal severe hyperparathyroidism. Cell 1993;75:1237-9.
32. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51:328-36.
33. Rodriguez M, Caravaca F, Fernández E, Borrego M, Lorenzo V, Cubero J et al. Parathyroid function as a determinant of the response to calcitriol treatment in the haemodialysis patient. Kidney Int 1999;56:306-17.
34. Ureña P, Kubrusly M, Mannstadt M, Hruby M, Trinh MM, Silve C et al. The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int 1994;45:605-11.
35. Ureña P, Mannstadt M, Hruby M, Ferreira A, Schmitt F, Silve C et al. Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats. Kidney Int 1995;47:1797-805.
36. Brown EM, Wilkson RE, Eastman RC, Pallota J, Marynick SP. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 1982;54:172-9.
37. Malberti F, Farina M, Imbasciati E. The PTH-calcium curve and set-point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transplant 1999;14:2398-406.
38. Felsenfeld AJ, Llach F. Parathyroid gland function in renal failure. Kidney Int 1993;43:771-89.
39. Ramirez JA, Goodman WG, Gornbein J, Menezes C, Moulton L, Segre GV et al. Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab 1993;76:1489-94.
40. Yamamoto M, Igarashi T, Muramatsu M, Fukagawa M, Motokura T, Ogata E et al. Hypocalcaemia increases and hypercalcaemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat. J Clin Invest 1989;83:1503-6.
41. Naveh-Many T, Rahamimov R, Liuni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate and vitamin D. J Clin Invest 1995;96:1786-93.
42. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986;78:1296-301.
43. Slatopolsky E, Lopez-Hilker S, Delmez J, Dusso A, Brown A, Martin KJ. The parathyroid-calcitriol axis in health and chronic renal failure. Kidney Int 1990;38 (Suppl. 29):S41-7.
44. 2D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 1986;119:2864-6.
45. Silver J, Naveh-Many T, Mayer H. Regulation by vitamin D metabolites of messenger ribonucleic acid for pre-proparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 1985;82:4270-3.
46. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seyno Y. Decrease 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436-42.
47. Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, Hirakata H et al. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 2002;62:1196-207.
48. 2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989;35:1049-56.
49. Delmez JA, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: a role for increase sensitivity to calcium. J Clin Invest 1989;83:1349-55.
50. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999;56 (Suppl. 73):S14-9.
51. Llach F, Massry SG. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 1985;61:601-6.
52. Reiss E, Canterbury JM, Bercovitz MA. The role of phosphate in the secretion of parathyroid hormone in man. J Clin Invest 1970;49:2146-9.
53. Kumar R. Metabolism of 1,25-dihydroxyvitamin D3. Physiol Rev 1984;64:478-504.
54. De Francisco A, Cobo MA, Setien MA, Rodrigo E, Fresnedo G, Unzueta M et al. Effect of serum phosphate on parathyroid hormone secretion during hemodialysis. Kidney Int 1998;54:2140-5.
55. Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996;28:596-602.
56. Abou-Samra A-B, Jüpner H, Force T. Expression cloning of a common receptor for parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA 1992;89:2732-6.
57. Ureña P, Mannstadt M, Hruby M. Down-regulation of the PTH/PTHrP receptor in uremia. J Bone Min Metab 1994;Sup. 12:87-90.
58. Ureña P, Ferreira A, Morieux C, Drücke T, Vernejoul M-C. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uremic rats. Nephrol Dial Transplant 1996.2008-16.
59. Block GA, Klassen PS, Lazarus M, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2008-18.
60. Floege J. When man turns to stone: Extra-osseous calcification in uremic patients. Kidney Int 2004;65:2447-62.
61. Essary LR, Wick MR. Cutaneous Calciphylaxis. An under-recognized clinicopathological entity. Am J Clin Pathol 2000;113:280-7.
62. Goodman WG. Vascular calcification in chronic renal failure. Lancet 2001;358:1115-6.
63. Coates T, Kirkland GS, Dymock RB, Murfhy BF, Brealey JK, Mathew TH et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998;32:384-91.
64. Llach F. Calcific uremic arteriolopathy (calciphylaxis): an evolving entity. Am J Kidney Dis 1998;32:514-8.
65. Couttenye MM, D'Haese P, Verschoren WJ, Behets G, Schrooten I, De Broe M. Low bone turnover in patients with renal failure. Kidney Int 1999;56 (Sup. 73):0-76.
66. Cannata-Andía JB. Hypokinetic azotemic osteodystrophy. Kidney Int 1998;54:1000-16.
67. Goodman WG, Veldhuis JD, Belin TR, Jupner H, Salusky IB. Suppressive effect of calcium on parathyroid hormone release in adynamic renal osteodystrophy and secondary hyperparathyroidism. Kidney Int 1997;51:1590-5.
68. Diaz-Lopez JB, Jorgetti V, Caorsi H, Ferreira A, Palma A, Menendez P et al. Epidemiology of renal osteodystrophy in Ibero-America. Nephrol Dial Transplant 1998;13:41-5.
69. Malluche H, Faugere MC. Risk of adynamic bone disease in dialysed patients. Kidney Int 1992;42 (Suppl. 38):62-7.
70. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J et al. Evidence for a normal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994;46:855-61.
71. Hodsman AB, Sherrard DJ, Alfrey AC, Off S, Brickman AS, Miller NL et al. Bone aluminum and hystomorphometric features of renal osteodistrophy. J Clin Endocrinol Metab 1982;54:539-46.
72. Sebert JL, Marié A, Guéris J. Assessment of the aluminum overload and its possible toxicity in asymptomatic uremic patients. Bone 1985;6:373-5.
73. Altmann P. Aluminum toxicity in dialysis patients: no evidence for a threshold serum aluminum concentration. Nephrol Dial Transplant 1993;8:25-34.
74. Marie P, Lomri A, de Vernejoul MC. Relationships between histomorphometric features of bone formation and bone cells characteristics in vitro in renal osteodystrophy. J Clin Endocrinol Metab 1989;69:166-73.
75. Hercz G, Pey Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG et al. Aplastic osteodystrophy without aluminum:The role of suppressed parathyroid function. Kidney Int 1993;44:860-6.
76. Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C et al. Renal osteodystrophy in diabetic patients. Kidney Int 1993;44:159-64.
77. Fournier A, Yvernau PH, Hué P, Said S, Hamdini N, Eldin HM et al. Adynamic bone disease in patients with uremia. Curr Opin Nephrol Hypert 1994;3:396-410.
78. Coburn JW. Mineral metabolism and renal bone disease: effects of CAPD versus hemodialysis. Kidney Int 1993;Sup. 40:92-100.
79. Cohen-Solal ME, Sebert JL, Boudailliez B, Westeel PF, Moriniere PH, Marie A et al. Adynamic bone disease in non dialysed uremic patients: a new type of osteopathy due to over treatment? Bone 1992;13:1-5.
80. Ferreira A, Ghazali A, Galvão J, Souberbielle JC, Jehle PM, Mohan S et al. Effect of type of dialysis membrane on bone in haemodialysis patients. Nephrol Dial Transplant 2001;16:1230-8.
81. Goodman W, Goldin J, Kuizon BD, Yoon G, Gales B, Sider D et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1472-83.
82. London GM, Marty C, Marchais SJ, Guerain AP, Metinier F, de Vernejoul M-C. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943-51.
83. Ellis HA, McCarthy JH, Herrington J. Bone aluminum in hemodialysed patients and in rats injected with aluminum chloride: relationship to impaired bone mineralisation. J Clin Pathol 1979;32:832-44.
84. 2D. Clin Nephrol 1981;15:18-22.
85. Ferreira A, Drücke TB. How to diagnose the different forms of renal osteodystrophy: Role of biochemical markers. Am J Med Sci 2000;320:85-9.
86. Ferreira A. Biochemical markers of bone turnover in the diagnosis of renal osteodystrophy: What do we have, what do we need? Nephrol Dial Transplant 1998;13:29-32.
87. DeVita MV, Rasenas LL, Bansal M, Glein GW, Zabetakis PM, Gardenswartz MH. Assessment of renal osteodystrophy in hemodialysis patients. Medicine 1992;71:284-90.
88. Malluche H, Monier-Faugere MC. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994;4:1631-42.
89. Ferreira A. Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods, when one biopsy is needed. Nephrol Dial Transplant 2000;15:8-14.
90. Dinarelo CA. Cytokines: Agents provocateurs in hemodialysis? Kidney Int 1992;41:683-94.
91. Santos FR, Moyses RM, Montenegro FL, Jorgetti V, Noronha IL. IL-1beta, TNF-alpha, TGF-beta and BFGF expression in bone biopsies before and after parathyroidectomy. Kidney Int 2003;63:899-907.
92. Herbelin A, Nguyen AT, Zingraff J, Urena P, Deschamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int 1990;37:116-25.
93. Herbelin A, Ureña P, Nguyen AT. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991;39:954-60.
94. Ferreira A, Simon P, Drücke T. Potencial role of cytokines in renal osteodystrophy. Nephrol Dial Transplant 1996;11:399-400.
95. Greenfield EM, Shaw SM, Gornik SA, Banks MA. Adenyl cyclase and interleukin-6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest 1995;96:1238-44.
96. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003;63 (Suppl. 85):S73-8.